Surgical management of both stage III and stage IV pulmonary carcinoid tumors confers survival benefit
Advanced-stage pulmonary carcinoid tumors are a rare entity, infrequently described in the literature. Through a large retrospective analysis spanning 26 years, we have identified risk factors associated with mortality for advanced-stage pulmonary carcinoid tumors and demonstrated a potential role for surgical therapy in stage IV disease.
Authors
- Cecilia Benz
- Jan Jenkins (ORCID: https://orcid.org/0000-0003-4925-7942)
- Vinicius Ernani (ORCID: https://orcid.org/0000-0002-1865-5801)
- Nathan Y. Yu (ORCID: https://orcid.org/0000-0003-4059-650X)
- Pedro Reck dos Santos (ORCID: https://orcid.org/0000-0002-5497-3188)
- Stephen D. Cassivi (ORCID: https://orcid.org/0000-0001-9600-0897)
- Jonathan D’Cunha
- Juan Farina (ORCID: https://orcid.org/0000-0002-5824-8485)
- Jason A. Wampfler (ORCID: https://orcid.org/0009-0007-6918-8135)
- Ping Yang (ORCID: https://orcid.org/0000-0002-8588-847X)
- Matthew Buras (ORCID: https://orcid.org/0000-0001-6503-0989)
- Yanmei Peng (ORCID: https://orcid.org/0000-0002-7801-8994)
- Zhong Gu
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- JTCVS Open
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1016/j.xjon.2025.06.005
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Mayo Foundation for Medical Education and Research
- National Institutes of Health